Roswell Park Cancer Institute: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 13 Leukemia, Lymphocytic, Chronic, B-Cell studies with Roswell Park Cancer Institute as lead sponsor. 1 are open to participants now and 8 have results posted.

Phase 1 3Phase 2 7No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone LymphomaCompletedNCT01682044Phase 2Results posted
• Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic LeukemiaTerminatedNCT01649791Not applicableResults posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00096044Phase 2Results posted
• Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic LeukemiaCompletedNCT00096018Phase 1/2Results posted
• Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic MalignanciesTerminatedNCT06343376Phase 1
• Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
• Azadirachta Indica in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT01251250Phase 1
• Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00054171Phase 2